Latest Investor Confidence News

Genesis Energy has completed a NZ$100 million share placement at NZ$2.15 per share, paving the way for a NZ$300 million rights offer to fund its renewable energy expansion under the Gen35 strategy.

Celsius Resources has raised A$9.3 million through a well-supported institutional placement, strengthening its balance sheet to advance the financing and early development of its flagship MCB copper-gold project in the Philippines.

3D Energi Limited remains suspended from ASX trading after failing to provide a crucial update on its funding status and exploration permit implications, prolonging market uncertainty.

Cadence Capital Limited has reported a remarkable turnaround with a 508% surge in profit after tax for the half-year ended December 2025, alongside a fully franked interim dividend declaration.

Paladin Energy has achieved a significant regulatory milestone with formal environmental approval for its Patterson Lake South uranium project in Saskatchewan, Canada, paving the way for construction licensing.

3D Energi Limited has offered 41.7 million free attaching options to investors from its October 2025 Placement, aiming to clear trading restrictions despite ongoing ASX suspension and financial challenges.

Ronin Resources has clarified the cause behind recent unusual trading activity, confirming no undisclosed information and announcing the end of negotiations on a potential copper-gold project in Argentina.

NAOS Small Cap Opportunities Company Limited reported a remarkable half-year profit surge and declared a steady quarterly dividend, despite portfolio returns lagging the benchmark index.

Paradigm Biopharmaceuticals has drawn down US$5 million from its Convertible Note Facility to fund the next phase of its global Phase 3 trial for knee osteoarthritis treatment, marking a key step as patient recruitment nears 50%.

Bell Financial Group delivered a robust 17.1% rise in net profit after tax to $36 million for 2025, driven by strong growth in its Platforms division and a rebound in market activity. The company declared a fully franked final dividend of 6.5 cents per share, signalling confidence as it prepares to launch a new wealth management platform in 2026.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

PathKey.AI Ltd has responded to ASX inquiries about a recent spike in its share price and trading volume, confirming no undisclosed information is driving the market activity. The company points to its recent strategic update and funding completion as context for investor interest.